Matchett Caroline L, Sahinkoc Mert, Chhatwal Jagpreet, Kisiel John B, Iyer Prasad G
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Best Pract Res Clin Gastroenterol. 2025 Mar;75:101980. doi: 10.1016/j.bpg.2025.101980. Epub 2025 Jan 9.
Barrett's esophagus screening is critical for early detection of esophageal adenocarcinoma, but optimal strategies remain debated. This systematic review analyzed thirteen studies evaluating screening cost-effectiveness through September 2024. Both traditional endoscopic and emerging non-endoscopic methods were cost-effective compared to no screening, with incremental cost-effectiveness ratios below standard willingness-to-pay thresholds. Non-endoscopic approaches, particularly swallowed cell collection devices with biomarkers, demonstrated superior cost-effectiveness versus standard endoscopy. Cost-effectiveness improved in populations with higher disease prevalence. Current evidence supports implementing screening programs, especially using non-endoscopic methods in high-risk populations. Future research should focus on validating risk stratification tools to further optimize screening approaches.
巴雷特食管筛查对于早期发现食管腺癌至关重要,但最佳策略仍存在争议。本系统评价分析了截至2024年9月评估筛查成本效益的13项研究。与不进行筛查相比,传统内镜检查和新兴的非内镜检查方法均具有成本效益,增量成本效益比低于标准支付意愿阈值。非内镜检查方法,特别是带有生物标志物的吞咽细胞采集装置,与标准内镜检查相比显示出更高的成本效益。在疾病患病率较高的人群中,成本效益有所提高。目前的证据支持实施筛查计划,尤其是在高危人群中使用非内镜检查方法。未来的研究应侧重于验证风险分层工具,以进一步优化筛查方法。